SIDE-BY-SIDE EVIDENCE

Compare evidence.
Keep the context.

Select 2–3 profiles from the English Library. Class and grade describe evidence and regulatory context, not comparative effectiveness or suitability for an individual.

Choose profiles

SIDE-BY-SIDE EVIDENCE VIEW

Compare selected profiles

Evidence comparison · not a treatment ranking

Evidence boundaries, not cross-trial treatment outcomes
Molecule	Cartalax / AED	Cortagen	Epitalon
Research Topic	Tissue / Repair Research	Neuro / Cognitive Research	Longevity / Aging Research
Pharmacology	AED tripeptide / T-31 candidate	AEDP tetrapeptide / experimental neurobiology	Experimental synthetic pineal-derived tetrapeptide
PrimeCore Class	Class ENeeds Verification	Class CExperimental / limited evidence	Class CExperimental / limited evidence
Evidence Grade	Grade EPreclinical evidence	Grade EPreclinical evidence	Grade CEarly human evidence
Evidence boundary	This profile reviews AED/T-31 evidence associated with the Cartalax name, without authenticating the supplier product. Skin-fibroblast and rat-kidney culture findings do not establish cartilage regeneration, arthritis treatment or human anti-ageing benefit. AED is distinct from AEDG and AEDP.	Cortagen is the AEDP tetrapeptide, distinct from Cortexin mixtures and AED/Cartalax. Rat nerve-regeneration and mouse-heart transcriptomic findings are preclinical. Background references to human effects are not controlled human evidence within those experiments.	An experimental tetrapeptide with limited human evidence; cell or biomarker findings do not establish human lifespan extension.
Unknowns	Insufficient data in the current dataset	Insufficient data in the current dataset	whether human-study material was free base, acetate or another formulation whether biomarker changes produce better sleep or any patient-important outcome efficacy and safety in people with diagnosed insomnia effects on human lifespan, healthspan, cancer risk and long-term organ function human pharmacokinetics, dose-response and route comparability independent replication beyond a concentrated research network current Thailand and Russia regulatory status pending direct official verification
Limitations	English translation is not yet verified for 1 excerpt(s). This is a language gap, not an absence of risks or uncertainty. Read original excerpts (Thai / mixed language) ชื่อ Cartalax ไม่ทำให้หลักฐานในไตหรือ fibroblast กลายเป็น clinical cartilage-regeneration evidence	English translation is not yet verified for 1 excerpt(s). This is a language gap, not an absence of risks or uncertainty. Read original excerpts (Thai / mixed language) AEDP ≠ Cortexin mixture ≠ AED/Cartalax; ยังไม่ยืนยัน clinical efficacy ของ Cortagen จากงานที่ทบทวน	The available human evidence is biomarker-focused, short-term and does not evaluate insomnia or longevity outcomes. Much of the broader literature comes from related investigators and mixes Epitalon with Epithalamin, a different pineal extract. Cell, mouse and primate findings cannot be merged into a human efficacy claim. FDA found no clinical safety studies and no evidence supporting insomnia treatment.
Sources	Author-group review · Cartalax/AED name mapping only, not clinical efficacy Skin fibroblasts · PMID 27259496 Kidney explants · PMID 26033601	Sciatic-nerve model · PMID 11276314 Mouse-heart transcriptomics · PMID 15159690	https://www.fda.gov/media/193345/download https://www.fda.gov/advisory-committees/advisory-committee-calendar/july-23-24-2026-meeting-pharmacy-compounding-advisory-committee-07232026 https://pubmed.ncbi.nlm.nih.gov/33280326/ https://pubmed.ncbi.nlm.nih.gov/12937682/ https://pubmed.ncbi.nlm.nih.gov/14501183/ https://pubmed.ncbi.nlm.nih.gov/29124531/ https://www.wada-ama.org/en/resources/world-anti-doping-program/prohibited-list https://products.mhra.gov.uk/
Read more	Read English overview Complete evidence profile (Thai)	Read English overview Complete evidence profile (Thai)	Read English overview Complete evidence profile (Thai)

This table does not compare doses, cross-trial outcomes or individual suitability. Missing information does not establish an absence of risk.

Choose another comparison

Continue reading

Missing fields mean information is unavailable in the current structured dataset, not that a molecule has no risks or uncertainties. English translations retain the original evidence boundaries. Where translation is not yet verified, the original Thai excerpts remain available under an explicit label. Sources retain their original language.

10 questions before drawing conclusions

Compare evidence.Keep the context.

Continue reading

Contact PrimeCoreBio

Compare evidence.
Keep the context.